Evercore ISI Reiterates Buy Rating on Travere Therapeutics
Evercore ISI maintains a buy rating on Travere Therapeutics with a $60 price target, a 7.24% upside from the current price.
Key Points
- Evercore ISI reiterated its buy rating on Travere Therapeutics, setting a price target of $60 as of June 18, 2026.
- Evercore ISI Group's $60 price target implies 7.24% upside from Travere Therapeutics, Inc.'s ($TVTX) current $55.95 share price.
- Shares of Travere Therapeutics traded at $54.14, close to their 52-week high of $55.11, with a market cap of $5.03 billion.
- Insiders, including Timothy Coughlin and Roy Baynes, engaged in both buying and selling activities on June 12, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Evercore ISI Group has reiterated its buy rating on Travere Therapeutics, Inc. (NasdaqGM: TVTX), setting a price target of $60. This update came on June 18, 2026, as the stock traded at $54.14, near its 52-week high of $55.11.
Travere Therapeutics, Inc. Stock Down 14.8%
Shares of NasdaqGM: TVTX traded near $54.14. Travere Therapeutics has a market cap of approximately $5.03 billion, with a forward P/E ratio of 11.15 and a beta of 1.141. The stock's 52-week range has been between $13.97 and $55.11, with a 50-day moving average of $43.33 and a 200-day moving average of $33.43. The company maintains a current ratio of 3.13 and a quick ratio of 2.82, although it carries a high debt-to-equity ratio of 331.88.
$TVTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Travere Therapeutics reported revenue of $536.2 million, showing a growth rate of 55.6%. Despite this, the company has a negative net margin of -3.995% and a return on equity of -69.383%, indicating it is currently not profitable. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Travere Therapeutics, Inc.
On June 12, 2026, insiders engaged in several transactions. Timothy Coughlin bought 10,000 shares at an average price of $26.52 and sold the same amount at $50.07. Roy Baynes purchased 4,500 shares at $21.38 and sold the same amount at $50.00. These trades were not part of any planned trading program.
Analysts Set New Price Targets
On June 18, 2026, Evercore ISI Group maintained its buy rating with a $60 price target. Other firms have also shown confidence, with Citigroup on June 15, 2026, maintaining a buy rating and a $70 target, and Wells Fargo setting a $65 target on June 12, 2026. In total, 14 analysts have a strong buy consensus with an average target price of $56.71.
About Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing therapies for rare kidney and metabolic diseases. The company markets FILSPARI, a medication for IgA Nephropathy, and Thiola for cystinuria. Travere's pipeline includes Sparsentan and Pegtibatinase, both targeting rare conditions. Led by CEO Dr. Eric M. Dube, the company employs 497 people.
Bottom Line
Evercore ISI's reaffirmation of its buy rating and $60 target price for Travere Therapeutics underscores its confidence in the company's prospects. Investors should note that 13F filings and analyst ratings are backward-looking and may not reflect current conditions. Tracking these updates helps investors gauge market sentiment and company performance.
Get Travere Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TVTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.